Simoctocog alfa - Octapharma

Drug Profile

Simoctocog alfa - Octapharma

Alternative Names: Factor VIII - Octapharma; Human-cl rhFVIII - Octapharma; Nuwiq; rFactor-VIII-Octapharma ; rFVIII-Octapharma

Latest Information Update: 23 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Developer Cardinal Health; Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 09 Oct 2018 Octapharma completes a phase IIIb trial in Haemophilia A in Canada, Croatia, Finland, France, Japan, Macedonia, Netherlands, Slovenia and USA (NCT02256917) (EudraCT2014-002986-30)
  • 20 Jun 2018 EMA approves an extension of marketing authorisation for Nuwiq® single dose vial strengths 2500, 3000 and 4000 IU for treatment of Haemophilia A in Europe
  • 09 Dec 2017 Pharmacokinetics data from the preclinical studies in Haemophilia A presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top